EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study

Hai-Hui Zhuang, Qiang Qu, Wen-Ming Long, Qin Hu, Xiao-Li Wu, Ying Chen, Qing Wan, Tian-Tian Xu, Yue Luo, Hai-Yan Yuan, Qiong Lu, Jian Qu

Infection · 2025-02 · 53 (1) · 95-106

DOI: 10.1007/s15010-024-02324-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Infection, online erschienen am 17.06.2024. Verfasst von Hai-Hui Zhuang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Central South University, No.139 Middl…. Hauptthemen laut MEDLINE: Klebsiella Infections, Ceftazidime, Polymyxin B, Azabicyclo Compounds. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Province Health and Family Planning Scientific Research Project, Scientific Research Project of Hunan Health Commission, Project of Hunan Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

In this retrospective observational multicenter study, we aimed to assess efficacy and mortality between ceftazidime/avibactam (CAZ/AVI) or polymyxin B (PMB)-based regimens for the treatment of Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections, as well as identify potential risk factors.

Methods

A total of 276 CRKP-infected patients were enrolled in our study. Binary logistic and Cox regression analysis with a propensity score-matched (PSM) model were performed to identify risk factors for efficacy and mortality.

Results

The patient cohort was divided into PMB-based regimen group ( n = 98, 35.5%) and CAZ/AVI-based regimen group ( n = 178, 64.5%). Compared to the PMB group, the CAZ/AVI group exhibited significantly higher rates of clinical efficacy (71.3% vs. 56.1%; p = 0.011), microbiological clearance (74.7% vs. 41.4%; p < 0.001), and a lower incidence of acute kidney injury (AKI) (13.5% vs. 33.7%; p < 0.001). Binary logistic regression revealed that the treatment duration independently influenced both clinical efficacy and microbiological clearance. Vasoactive drugs, sepsis/septic shock, APACHE II score, and treatment duration were identified as risk factors associated with 30-day all-cause mortality. The CAZ/AVI-based regimen was an independent factor for good clinical efficacy, microbiological clearance, and lower AKI incidence.

Conclusions

For patients with CRKP infection, the CAZ/AVI-based regimen was superior to the PMB-based regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella InfectionsCeftazidimePolymyxin BAzabicyclo CompoundsAnti-Bacterial AgentsKlebsiella pneumoniaeCarbapenem-Resistant EnterobacteriaceaeHumansMaleFemaleDrug CombinationsRetrospective StudiesAgedMiddle AgedPropensity ScoreTreatment OutcomeRisk FactorsAged, 80 and overCarbapenems

Stichwörter der Autor:innen

Carbapenem-resistant Klebsiella pneumoniae (CRKP)Ceftazidime/avibactam (CAZ/AVI)Clinical efficacyMicrobiological clearanceMortalityPolymyxin B (PMB)

Substanzen

Ceftazidimeavibactam, ceftazidime drug combinationPolymyxin BAzabicyclo CompoundsDrug CombinationsAnti-Bacterial AgentsCarbapenems

Autor:innen und Institutionen

  • Department of Pharmacy, the Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Central South University, No.139 Middle Renmin Road, Changsha, 410011, China.
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410078, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410078, China.
  • Institute of Hospital Management, Central South University, Changsha, 410078, China.
  • Department of Pharmacy, Second People's Hospital of Huaihua City (The Central Hospital of Huaihua City), Jingzhou District, Huaihua, 418400, China.
  • Department of Pharmacy, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.

Förderung

  • Hubei Province Health and Family Planning Scientific Research Project
  • Scientific Research Project of Hunan Health Commission
  • Project of Hunan Natural Science Foundation
  • Degree & Postgraduate Education Reform Project of Central South University
  • BEIJING Medical and health foundation

Zitieren

APA

Zhuang, H. H., Qu, Q., Long, W. M., Hu, Q., Wu, X. L., Chen, Y., Wan, Q., Xu, T. T., Luo, Y., Yuan, H. Y., Lu, Q., & Qu, J. (2025). Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study. Infection, 53(1), 95-106. https://doi.org/10.1007/s15010-024-02324-8

Vancouver

Zhuang HH, Qu Q, Long WM, Hu Q, Wu XL, Chen Y, et al. Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study. Infection. 2025;53(1):95-106. doi:10.1007/s15010-024-02324-8

BibTeX
@article{Zhuang2025,
  author = {Zhuang, Hai-Hui and Qu, Qiang and Long, Wen-Ming and Hu, Qin and Wu, Xiao-Li and Chen, Ying and Wan, Qing and Xu, Tian-Tian and Luo, Yue and Yuan, Hai-Yan and Lu, Qiong and Qu, Jian},
  title = {Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study},
  journal = {Infection},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {95--106},
  doi = {10.1007/s15010-024-02324-8}
}
Kostenlos starten →